Emergent BioSolutions Announces Exercise by BARDA of the First Contract Option, Valued at $261 Million, to Procure Doses of AV7909 Anthrax Vaccine Candidate for the Strategic National Stockpile

July 30, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search